Transforming gene therapy through the discovery and detection of complex genetic changes
Direct, Definitive Genomics
KromaTiD supports research teams in academia, large pharmaceutical, and therapeutic companies with expert scientific support and unparalleled genomics tools and services. We are your partner for biomarker discovery, genotoxicity studies, clone screening assessment of editing-associated errors, and plasmid manufacturing.
Products
KromaTiD’s suite of next-level molecular tools produce robust, easily enumerable fluorescent signals enabling you to optimize your traditional FISH process. Our patented directional Genomic Hybridization™ technology provides superior assays, and by utilizing our preparation method, you can now prepare the cells in your lab.
Services
KromaTiD’s service offerings put patented directional Genomic Hybridization™ technology at your disposal to generate data that’s out of reach of other platforms. Our experts collaborate with your team do design the assay, vet the data and back the results with orthogonal testing like traditional G-banded karyotyping. Plasmid manufacturing and cell culture services are supplied economically, with a fast turnaround in order to complete your crucial research projects.
Applications
Whether your research involves gene editing, cell and gene therapeutics, new oncology treatment strategies, or seeking a state-of-the-art approach to biodosimetry, KromaTiD offers a customizable set of services backed by an expert science team ready to collaborate with you, and unparalleled molecular tools to rival that of our competitors.
KromaTiD News
Company News | Press
- KromaTiD Announces Launch of dGH Cell Prep Kit
- KromaTiD Announces Launch of Pinpoint FISH™ DNA Probes
- Just Up on the Blog! KromaTiD’s Dark Lab Files: The Great Race to Cure Cancer – CAR-T Segment
- Register for KromaTiD’s directional Genomic Hybridization™ Webinar Featured on GEN News April 27th
- Just Up on the Blog! KromaTiD’s Dark Lab Files: Cytogenetics a Little History Lesson
- KromaTiD Announces Launch of Cell Culture Services
- KromaTiD Announces EARLY ACCESS Launch of TP53/CEP17 Kit for Synthetic Oligonucleotide-Based FISH Assay
- KromaTiD Announces Launch of dGH SCREEN™
- Applied Spectral Imaging and KromaTiD announce strategic commercial partnership
- KromaTiD and dGH in-Site featured in Genetic Engineering & Biotechnology News
Videos | Presentations | Webinars
- KromaTiD Webinar dGH SCREEN October 4, 2022
- KromaTiD Webinar CRISPR Off Target Gene Editing (GEN News)
- KromaTiD Presents at Next Gen Omics Boston
- KromaTiD’s Cell Culture Services Protocol
- Dr. Chris Tompkins and Erin Cross present webinar for the launch of dGH SCREEN™ for unbiased whole genome analysis of chromosomal structural rearrangements
- Dr. Lauren Kinner-Bibeau presents webinar on single-cell measurements of genomic inserts and transgenes
- KromaTiD presents at the 2020 virtual NextGen Omics Series
- KromaTiD CTO Dr. Chris Tompkins presents at the 2020 Cell & Gene Therapy Virtual Congress
Market News
- AstraZeneca Deepens Cancer Cell Therapy Portfolio with Neogene Buyout
- Harmonizing the Community of Genome Editing with the First Set of Standardized Terms (NIST)
- GSK’s CAR-T rival Blenrep fails multiple myeloma trial, endangering its accelerated approval
- Novartis’ $3B Prospect beats AstraZeneca Blockbuster in Phase 3
- Prime Medicine Raises $175M in one of the year’s largest Biotech IPO’s
- Bluebird on a Roll with Second FDA Approval in Matter of Weeks
- Intellia’s Latest Data Indicates Full Potential of CRISPR
- Guardant, Merck KGaA expand precision therapeutics collab, focusing on hard-to-treat cancer
- J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
- Eagle swoops down to nab chunk of BARDA-backed Enalare Therapeutics